Avenzo Therapeutics has disclosed the promising clinical phase CDK2 inhibitor known as AVZO-021, originally developed by Allorion Therapeutics.

Inspirna teams up with German-based Merck KGaA to expedite the worldwide advancement of the drug Ompenaclid, known as RGX-202

Debiopharm is collaborating with Repare Therapeutics to investigate combining PKMYT1 and WEE1 inhibitors as a potential cancer treatment strategy.

KYV-101, a therapeutic agent by Kyverna, has been granted approval by the American FDA for use in a Phase 2 study, KYSA-7, targeting individuals suffering from advanced, treatment-resistant Multiple Sclerosis.

GPN Vaccines Announces Encouraging Safety and Immunogenic Response Results in Initial Phase Trial of its Gamma-PN Vaccine.

Bayer AG and its independent subsidiary Asklepios BioPharmaceutical, Inc., focused on gene therapy, have completed data collection for the AB-1005 (AAV2-GDNF) Phase Ib trial after 18 months.

Genascence Corporation has launched a Phase 1b clinical study to evaluate the efficacy of their gene treatment, codenamed GNSC-001, targeting knee osteoarthritis.

Upstream Bio has initiated the first patient treatments in a Phase II study on Verekitug (UPB-101) targeting Chronic Rhinosinusitis with Nasal Polyps.

Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.

Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).

OBI Pharma announced the FDA has approved its investigational new drug application for OBI-992, allowing the start of a phase 1/2 clinical trial to evaluate their novel TROP2-targeted antibody-drug conjugate for cancer treatment.

Belief BioMed Group announced the start of patient treatment in a major BBM-H803 study. This gene therapy aims to treat hemophilia A and is independently developed by Belief BioMed.